Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (9)
Type
(
1 selected
)
Type
Guidance (280)
Guidance programme
(
1 selected
)
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 101 to 110 of 280
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312
Technology appraisal guidance
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]
Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071
Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]
Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Technology appraisal guidance
Iclepertin for treating cognitive impairment associated with schizophrenia ID6483
Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491
Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376
Technology appraisal guidance
Previous page
1
…
9
10
Current page
11
12
13
…
28
Page
11
of
28
Next page
Results per page
10
25
50
All
Back to top